Industry
Biotechnology
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Loading...
Open
4.03
Mkt cap
992M
Volume
4.1M
High
4.12
P/E Ratio
-3.27
52-wk high
7.45
Low
3.53
Div yield
N/A
52-wk low
3.06
Portfolio Pulse from
November 08, 2024 | 9:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 1:10 pm
Portfolio Pulse from Benzinga Insights
October 02, 2024 | 12:05 pm
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:07 am
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 9:52 am
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 11:14 am
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:11 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.